Is it safe to give Miralax (polyethylene glycol 3350) to a 9‑year‑old for occasional constipation, and what is the appropriate dose?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 20, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

MiraLAX (Polyethylene Glycol 3350) for a 9-Year-Old Child

Yes, MiraLAX is safe and effective for a 9-year-old with occasional constipation; start with 0.7–0.8 g/kg/day (approximately 17 g once daily for most 9-year-olds) mixed in at least 4–8 ounces of liquid, and expect the first bowel movement within 2–4 days. 1, 2

Dosing Guidelines for Pediatric Patients

Standard maintenance dose:

  • The effective pediatric dose is 0.7–0.8 g/kg/day, which translates to approximately 17 g once daily for most 9-year-olds (assuming average weight of 25–30 kg). 1
  • Mix the powder in at least 4–8 ounces of liquid (water, juice, soda, coffee, or tea). 1, 2
  • Juices containing sorbitol provide a synergistic osmotic effect and may enhance efficacy. 1

Initial treatment approach:

  • Continue therapy for 1–2 weeks to achieve optimal effect before assessing response. 1, 3
  • The first bowel movement typically occurs within 2–4 days of starting treatment. 2

Safety Profile in Children

MiraLAX is well-established as safe in pediatric populations:

  • Multiple studies confirm safety and efficacy in children, with an average treatment duration of 8.4 months in pediatric trials. 1
  • The medication has been shown safe for 6–12 months or more of continuous use when needed. 1
  • Common adverse effects include mild abdominal distension, flatulence, and nausea, which are generally dose-dependent and mild. 1, 3

Important caveat regarding FDA labeling:

  • The FDA label states "should not be used by children," but this reflects the original approval for occasional constipation in adults only. 2
  • However, the American Academy of Pediatrics and American Gastroenterological Association both explicitly recommend PEG 3350 as first-line therapy for pediatric constipation, superseding the restrictive FDA language. 1, 3
  • Extensive pediatric research, including studies in children as young as 3 months, demonstrates excellent safety and efficacy. 4, 5

Critical Implementation Points to Avoid Treatment Failure

Adequate fluid mixing and daily hydration:

  • Insufficient liquid volume is the most common cause of treatment failure. 1
  • The powder must be dissolved in a minimum of 4 ounces, preferably 8 ounces, of liquid. 1, 3
  • Ensure the child maintains adequate daily fluid intake throughout the day beyond just the mixing liquid, as PEG requires water to work osmotically. 1

Pre-treatment assessment:

  • Rule out bowel obstruction or paralytic ileus before starting therapy. 1
  • Check for fecal impaction, which may require manual disimpaction or enema first before initiating PEG therapy. 1

When to Escalate Therapy

If no bowel movement after 3–4 days of optimal PEG therapy:

  • Add a bisacodyl suppository (10 mg) or glycerin suppository while continuing PEG. 1
  • Alternatively, add an oral stimulant laxative (senna or bisacodyl) to the PEG regimen to exploit complementary mechanisms (osmotic softening plus colonic motility enhancement). 1, 3

If constipation persists despite adequate dosing and compliance:

  • Consider increasing the dose gradually based on response and tolerability. 1, 3
  • Reassess for adequate fluid intake and compliance before assuming treatment failure. 1

Duration of Therapy

Maintenance approach:

  • Continue maintenance dosing once bowel movements normalize rather than stopping abruptly. 1
  • The therapeutic response is durable for up to 6 months, supporting long-term use when clinically indicated. 1, 3
  • After achieving several satisfactory bowel movements (typically 1–2 weeks), discuss with the child's physician whether to continue or taper therapy. 2

Common Clinical Pitfalls

  • Not confirming adequate fluid intake beyond the mixing liquid leads to treatment failure. 1
  • Assuming treatment failure without first optimizing dose and ensuring compliance can lead to premature discontinuation. 1
  • Delaying rectal intervention beyond 3–4 days increases the risk of fecal impaction. 1
  • Stopping therapy too abruptly after initial success may result in recurrence; gradual weaning is preferred. 1

References

Guideline

Pediatric Dosing of MiraLAX (Polyethylene Glycol 3350)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Polyethylene Glycol 3350 (MiraLAX) for Chronic Constipation – Evidence‑Based Recommendations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Polyethylene glycol for constipation in children younger than eighteen months old.

Journal of pediatric gastroenterology and nutrition, 2004

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.